Tessera Defense & Homeland Security Inc.

BiomX Inc. is a clinical-stage biotechnology company that develops therapies using natural and synthetic bacteriophage technologies. Its phage treatments are engineered to target and eliminate specific pathogenic bacteria associated with chronic medical conditions, particularly diabetic foot infections. The company's pipeline includes fixed multi-phage cocktails such as BX011 and personalized phage approaches like BX211, both designed to combat Staphylococcus aureus infections. These therapeutic candidates serve patient populations suffering from diabetic foot ulcers and diabetic foot osteomyelitis, offering alternatives or complements to conventional antibiotic regimens.

The company maintains its principal executive offices in Dover, Delaware, and holds Delaware corporate registration. Historically, core operations and personnel were situated in Israel through its subsidiary, BiomX Ltd., which entered insolvency proceedings. BiomX has concentrated its clinical and preclinical studies on bacterial targets across the United States and international markets, while also collaborating with entities such as the U.S. Defense Health Agency and the National Institutes of Health.

Summary of the business section of Tessera Defense & Homeland Security's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 20 full-time employees.”